3The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Antithrombotic therapy during percutaneous coronary intervention.Chest,2004,126:576S-599S 被引量：1
4Patrono C,Coller B,Fitz Gerald GA,et al.Platelet-active drugs:the relationships among dose,effectiveness,and side effects:the Seventh ACCP Conference on Antithrombotic and Thrembclytic Therapy.Chest,2004,126(3 Supp 1):S234-S264 被引量：1
5Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients.BMJ,2002,324:71-86 被引量：1
6Mehta SR,Yusuf S,Peters RJ,et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCICURE study.Lancet,2001,358:527-533 被引量：1
7Akbulut M,Ozbay Y,Karaca I et al.The effect of long-term clopidogrel use on neointimal formation after percumncons coronary intervention.Coron Artery Dis,2007,15(6):347-352 被引量：1
8Wiviot SD,Trenk D,Frelinger AL.Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned perculancous coronary intervention.Circulation,2007,116:2923-2932 被引量：1
9Steen H,Lehrke S,Wiegand UK,et al.Very early cardiac magnetic resonance imping for quantification of myocardial tissue perfosion in patients receiving tirefiban before pereutanecns coronary intervention for ST-elevation myocardial infarction.Am Heart J,2005,149(3):564 被引量：1
10Valgimigli M,Percoco G,Barbieri D,et al.The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty:The ADVANCE Trial.J Am Coll Carcliol,2004,44(1):14-19 被引量：1
